App aims to boost cancer patients' well-being at home
NCT ID NCT06379880
First seen Feb 04, 2026 · Last updated Jun 20, 2026 · Updated 18 times
Summary
This completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and quality of life compared to standard care. The study measured changes in quality-of-life scores after 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Saint-Etienne
Saint-Priest-en-Jarez, 42270, France
-
Centre Hospitalier de Morlaix
Morlaix, 29600, France
-
Centre Paul Strauss
Strasbourg, 67033, France
-
Centre d'oncologie de Gentilly
Nancy, 54100, France
-
Chu Dupuytren
Limoges, 87042, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Hôpitla privé des Côtes d'Armor - Centre CARIO-HPCA
Plérin, 22190, France
-
Institut Jean Godinot
Reims, 51100, France
-
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, De, 54519, France
-
Polyclinique de Blois
Blois, 41260, France
-
Pôle Santé République
Clermont-Ferrand, 63000, France
-
Sainte-Catherine, Institut du Cancer Avignon-Provence
Avignon, 84918, France
-
centre Georges François Leclerc
Dijon, 21079, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CONTINUUM+ CONNECT remote monitoring platform (digital device)
What this could lead to
If successful, this could show that remote monitoring helps cancer patients feel better and manage symptoms at home.
What could go wrong
This is a completed study, but it only measures quality of life over 3 months, not survival or cure. Results may not apply to all cancer types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.